phentermine has been researched along with Hypertension in 10 studies
Phentermine: A central nervous system stimulant and sympathomimetic with actions and uses similar to those of DEXTROAMPHETAMINE. It has been used most frequently in the treatment of obesity.
Hypertension: Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more.
| Excerpt | Relevance | Reference |
|---|---|---|
| "There is a perception that phentermine pharmacotherapy for obesity increases blood pressure and heart rate (HR), exposing treated patients to increased cardiovascular risk." | 7.77 | Blood pressure and heart rate effects, weight loss and maintenance during long-term phentermine pharmacotherapy for obesity. ( Greenway, FL; Gupta, AK; Hendricks, EJ; Westman, EC, 2011) |
| "In people with elevated blood pressure, orlistat, phentermine/topiramate and naltrexone/bupropion reduced body weight; the magnitude of the effect was greatest with phentermine/topiramate." | 5.12 | Long-term effects of weight-reducing drugs in people with hypertension. ( Berghold, A; Horvath, K; Jeitler, K; Krenn, C; Semlitsch, T; Siebenhofer, A; Winterholer, S, 2021) |
| "There is a perception that phentermine pharmacotherapy for obesity increases blood pressure and heart rate (HR), exposing treated patients to increased cardiovascular risk." | 3.77 | Blood pressure and heart rate effects, weight loss and maintenance during long-term phentermine pharmacotherapy for obesity. ( Greenway, FL; Gupta, AK; Hendricks, EJ; Westman, EC, 2011) |
| "Nineteen participants, all of whom had hypertension, were being treated with fenfluramine or dexfenfluramine (5 on these agents alone, 14 also with phentermine)." | 3.71 | Appetite suppressants and valvular heart disease in a population-based sample: the HyperGEN study. ( Arnett, DK; Bella, JN; de Simone, G; Devereux, RB; Hopkins, PN; Kitzman, DW; Liu, JE; Morgan, D; Oberman, A; Palmieri, V; Roman, MJ, 2002) |
| "To evaluate, in compliant patients, the pharmaceutical costs of treating obesity with fenfluramine/mazindol, fenfluramine/phentermine, caffeine/ephedrine, or mazindol relative to the pharmaceutical costs of treating obesity-related comorbid conditions and reducing cardiovascular risk." | 3.70 | Pharmaceutical cost savings of treating obesity with weight loss medications. ( Bray, GA; Greenway, FL; Rood, JC; Ryan, DH; Smith, SR; Tucker, EW, 1999) |
| "Hypertension is a major risk factor for cardiovascular and renal diseases in the United States and worldwide." | 2.72 | Weight-Loss Strategies for Prevention and Treatment of Hypertension: A Scientific Statement From the American Heart Association. ( Ard, JD; Cohen, JB; Egan, BM; Hall, JE; Hall, ME; Lavie, CJ; Ma, J; Ndumele, CE; Schauer, PR; Shimbo, D, 2021) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (10.00) | 18.7374 |
| 1990's | 2 (20.00) | 18.2507 |
| 2000's | 2 (20.00) | 29.6817 |
| 2010's | 2 (20.00) | 24.3611 |
| 2020's | 3 (30.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hall, ME | 1 |
| Cohen, JB | 1 |
| Ard, JD | 1 |
| Egan, BM | 1 |
| Hall, JE | 1 |
| Lavie, CJ | 1 |
| Ma, J | 1 |
| Ndumele, CE | 1 |
| Schauer, PR | 1 |
| Shimbo, D | 1 |
| Siebenhofer, A | 2 |
| Winterholer, S | 1 |
| Jeitler, K | 2 |
| Horvath, K | 2 |
| Berghold, A | 2 |
| Krenn, C | 1 |
| Semlitsch, T | 2 |
| Chua, MWJ | 1 |
| Lai, BC | 1 |
| Posch, N | 1 |
| Meschik, J | 1 |
| Hendricks, EJ | 1 |
| Greenway, FL | 2 |
| Westman, EC | 1 |
| Gupta, AK | 1 |
| Stephens, LC | 1 |
| Katz, SG | 1 |
| Derby, LE | 1 |
| Myers, MW | 1 |
| Jick, H | 1 |
| Ryan, DH | 1 |
| Bray, GA | 1 |
| Rood, JC | 1 |
| Tucker, EW | 1 |
| Smith, SR | 1 |
| Palmieri, V | 1 |
| Arnett, DK | 1 |
| Roman, MJ | 1 |
| Liu, JE | 1 |
| Bella, JN | 1 |
| Oberman, A | 1 |
| Kitzman, DW | 1 |
| Hopkins, PN | 1 |
| Morgan, D | 1 |
| de Simone, G | 1 |
| Devereux, RB | 1 |
| Hoyer, I | 1 |
| Van Zwieten, PA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Long-term Phentermine Pharmacotherapy: An Investigation for Symptoms of Dependence, Cravings, or Withdrawal[NCT01402674] | 269 participants (Actual) | Interventional | 2011-08-31 | Completed | |||
| [NCT00005267] | 3,604 participants (Actual) | Observational | 1995-09-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for phentermine and Hypertension
| Article | Year |
|---|---|
Weight-Loss Strategies for Prevention and Treatment of Hypertension: A Scientific Statement From the American Heart Association.
Topics: American Heart Association; Anti-Obesity Agents; Appetite Depressants; Bariatric Surgery; Exercise; | 2021 |
Long-term effects of weight-reducing drugs in people with hypertension.
Topics: Adult; Anti-Obesity Agents; Appetite Depressants; Bias; Blood Pressure; Body Weight; Bupropion; Diet | 2021 |
Long-term effects of weight-reducing drugs in people with hypertension.
Topics: Adult; Anti-Obesity Agents; Appetite Depressants; Blood Pressure; Cyclobutanes; Diet, Reducing; Fema | 2016 |
7 other studies available for phentermine and Hypertension
| Article | Year |
|---|---|
Phentermine-Induced Acute Kidney Injury Secondary to Uncontrolled Hypertension in a Patient with Weight Regain Post-bariatric Surgery.
Topics: Acute Kidney Injury; Bariatric Surgery; Humans; Hypertension; Obesity, Morbid; Phentermine; Weight G | 2021 |
Blood pressure and heart rate effects, weight loss and maintenance during long-term phentermine pharmacotherapy for obesity.
Topics: Adult; Anti-Obesity Agents; Blood Pressure; Cohort Studies; Diet, Carbohydrate-Restricted; Diet, Ket | 2011 |
Phentermine and anaesthesia.
Topics: Alfentanil; Androstanols; Anesthesia; Anesthetics, Intravenous; Appetite Depressants; Blood Pressure | 2005 |
Use of dexfenfluramine, fenfluramine and phentermine and the risk of stroke.
Topics: Aged; Appetite Depressants; Body Mass Index; Case-Control Studies; Cerebrovascular Disorders; Cohort | 1999 |
Pharmaceutical cost savings of treating obesity with weight loss medications.
Topics: Adolescent; Adult; Appetite Depressants; Caffeine; Cardiovascular Diseases; Diabetes Mellitus; Drug | 1999 |
Appetite suppressants and valvular heart disease in a population-based sample: the HyperGEN study.
Topics: Aortic Valve Insufficiency; Appetite Depressants; Dexfenfluramine; Drug Combinations; Female; Fenflu | 2002 |
The central hypotensive action of amphetamine, ephedrine, phentermine, chlorphentermine and fenfluramine.
Topics: Amphetamine; Animals; Appetite Depressants; Blood Pressure; Cats; Chlorphentermine; Depression, Chem | 1972 |